Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention as a novel anticancer agent. However, its efficiency may be diminished by occurring resistance in cancer cells. The mechanisms of TRAIL resistance in melanoma are still unsolved. Here we show for the first time that TRAILinduced activation of NF-jB occurs in apoptosis-sensitive melanoma cell lines through TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4), whereas TRAIL failed to activate nuclear factor kappa B (NF-jB) in melanoma cells positive only for TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5). However, activation of NF-jB by TRAIL was not associated with enhanced expression of antiapoptotic factors: cellular FLICE-inhibitory protein (c-FLIP), Bcl-x L , X-linked inhibitor of apoptosis protein (XIAP), Survivin, Livin. Rather in one of the cell lines, TRAIL induced the downregulation of DR4. In an established cell culture model for TRAIL resistance and regained TRAIL sensitivity, resistance was neither associated with increased NF-jB activity by TRAIL nor by an increased expression of antiapoptotic proteins. However, significant downregulation of caspase-8, caspase-10 and of DR4 was characteristic for TRAILresistant, DR4-positive melanoma cells, and regained TRAIL sensitivity coincided with re-expression of these factors. Sensitivity was also largely retained after their exogenous overexpression. Thus, initiator caspases and DR4 rather than NF-jB may control melanoma cell sensitivity to TRAIL, and strategies, which result in their upregulation, may be useful for enhancement of TRAIL sensitivity.
Introduction
Malignant melanoma, the most aggressive skin cancer, has increased in incidence over the past decades and is characterized by an unbroken high mortality (Lens and Dawes, 2004) . Of major significance is its high metastatic potential as well as apoptosis resistance which substantially contributes to immune escape mechanisms as well as to inefficiency of chemotherapy (Soengas and Lowe, 2003) . Thus, new therapeutic strategies are urgently needed to improve the dismal prognosis of this disease.
The cytokine tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) of the TNF family of ligands binds to two death receptors, DR4 and DR5 (TRAIL-R1, TRAIL-R2), as well as to the three decoy receptors DcR1, DcR2 and osteoprotegerin (TRAIL-R3, TRAIL-R4, OPG) (Ashkenazi, 2002) . The downstream signalling cascade includes receptor oligomerization, formation of the death-inducing signalling complex (DISC), activation of initiator caspases, cleavage of effector caspases and finally DNA fragmentation (Wang and El Deiry, 2003) . In parallel, TRAIL may also trigger additional pathways such as nuclear factor kappa B (NF-kB) and mitogen-activated protein (MAP) kinases (Di Pietro and Zauli, 2004) .
TRAIL has attracted considerable attention owing to its selective killing of tumor cells while normal cells were largely protected (LeBlanc and Ashkenazi, 2003) . In animal models, treatment with TRAIL as a single agent or in combination with chemotherapeutics resulted in suppression of tumor xenografts without obvious signs of systemic toxicity (Walczak et al., 1999; Kelley and Ashkenazi, 2004) . Moreover, first clinical trials with TRAIL itself or with agonistic monoclonal antibodies against DR4 and DR5, respectively, have been reported for patients with non-small-cell lung cancer, nonHodgkin's lymphoma and colorectal carcinoma (Fischer and Schulze-Osthoff, 2005) .
However, frequent occurring of resistance to TRAIL appears as a major barrier for the development of efficient therapies (Wang and El Deiry, 2003) . Resistance to TRAIL, as for other drugs, has been suggested to result from increased levels of antiapoptotic factors such as c-FLIP, Bcl-2, Bcl-x L and inhibitors of apoptosis proteins (IAPs) (Zhang and Fang, 2005) . As the transcription factor NF-kB is activated by TRAIL and drives the transcription of several above listed antiapoptotic proteins, it was discussed as a critical regulator for enabling TRAIL resistance (Ivanov et al., 2003) .
NF-kB exerts a leading role in immune response and inflammation but has also been unmasked as supporting tumor progression, angiogenesis, metastasis and apoptosis resistance (Ravi and Bedi, 2004) . Five NF-kB subunits have been described (p65/RelA, c-Rel, p50/ p105, p52/p100 and RelB), which form homo-and heterodimers. The most common dimer consists of p65 and p50. Without stimulation, NF-kB is retained in the cytoplasm due to interaction with its inhibitors (Ik-Bs), which themselves are prone to degradation by the proteasome pathway (Karin and Ben Neriah, 2000) . In this way, proteasome inhibitors may block NF-kB activation.
In a previous study, we have demonstrated the high susceptibility of DR4-positive melanoma cells for TRAIL-induced apoptosis. As DR4 was also found to be expressed in the majority of primary melanomas, TRAIL and DR4-based approaches may be promising strategies for treatment of malignant melanoma (Kurbanov et al., 2005) . In the present paper, we addressed the nature of TRAIL resistance in melanoma cells. Therefore, a cell culture model of TRAIL-resistant cells and cells that have retained sensitivity has been established. Cells were investigated for NF-kB activation and for expression of pro-and antiapoptotic proteins. As for TRAIL-induced apoptosis, DR4 turned out to be the major player for TRAIL-induced NF-kB activation in melanoma cells. However, high NF-kB activation did not contribute to TRAIL resistance, rather, downregulation of initiator caspases and DR4 were proven to correlate with resistance to TRAIL.
Results

DR4-positive melanoma cells reveal high NF-kB activation after TRAIL treatment
For subsequent investigations, five melanoma cell lines and cultures of normal human melanocytes (NHM) were applied. According to our previous investigation (Kurbanov et al., 2005) , the cell lines were subdivided into sensitive (A-375, SK-Mel-13, Mel-HO) and resistant to TRAIL-induced apoptosis (SK-Mel-23, MeWo and NHM). Two cell lines (A-375, SK-Mel-13) were positive for DR4 and DR5, whereas Mel-HO, SK-Mel-23, MeWo and NHM only expressed DR5.
To determine whether TRAIL may induce nuclear translocation and activation of NF-kB, four melanoma cell lines and two NHM cultures were investigated by an enzymelinked immunosorbent assay (ELISA) specific for the five subunits of p50, . Levels of c-Rel, Rel-B and p52 remained unchanged upon TRAIL treatment (100 ng/ml, 1 h) in all cell lines. Nuclear translocation was, however, seen for p65 and p50 in the DR4-positive cell lines A-375 and SK-Mel-13 (Po0.05), whereas there was no significant change in NF-kB-binding activities in cells lacking DR4 (Figure 1a) .
A highly comparable activation pattern was obtained when investigating the cells by electrophoretic mobility shift assay (EMSA) analysis. Interestingly, the TRAILsensitive Mel-HO showed the highest constitutive nuclear binding activities, whereas the TRAIL-resistant SK-Mel-23 did not reveal significant activities. Identity of NF-kB subunits in the complexes was proven by supershift analysis, which was highly indicative for p65/ p50 dimers (Figure 1b) . Thus, NF-kB activation by TRAIL was restricted to DR4-positive melanoma cells.
To find out whether NF-kB activation was completely blocked in DR4-negative cells, its binding activity was also determined in Mel-HO and A-375 after treatment with TNF-a (10 ng/ml, 1 h). Unlike to TRAIL, TNF-a showed some increase of p65 NF-kB nuclear-binding activity in Mel-HO, which was also statistically significant (Po0.05; Figure 1c ). Dose-response curves for A-375 as well as kinetic analyses for A-375 and Mel-HO were established for the binding activities of p65 and p50 as well as for the apoptotic response. A significant dose-dependent increase of nuclear binding activities was seen in A-375 for both NF-kB subunits, starting with 20 ng/ml TRAIL. Apoptosis, which was determined after 6 h, already started to increase in A-375 at TRAIL concentrations above 1 ng/ml (Figure 1d ). The kinetic analysis of NF-kB-binding activity revealed an increase for both subunits as early as 1 h after TRAIL stimulation (100 ng/ml), and it reached its peak after 2 h in A-375. Apoptosis induction tightly followed NF-kB activation starting at 1 h after TRAIL stimulation (Figure 1d ).
These results display that TRAIL signalling led to apoptosis already at low concentrations, whereas NF-kB activation required higher concentrations. Furthermore, apoptosis and NF-kB activation after TRAIL stimulation were largely in parallel in DR4-positive A-375 cells, whereas there was no NF-kB activation in DR4-negative Mel-HO over the whole period of observation (12 h).
Increased NF-kB activity by TRAIL is mediated thought DR4 For determining which death receptor triggers NF-kB activation in cell lines positive for both TRAIL receptors, blocking antibodies were applied, which specifically bind and inactivate DR4 and DR5, respectively. The selective activity of these antibodies had been proven in our previous investigation, where DR4 antibodies abolished apoptosis in DR4-positive cells, whereas DR5 antibodies abolished apoptosis in DR4-negative (DR5-positive) cells (Kurbanov et al., 2005) . Here, blocking of DR4 largely abolished the increased binding activities (p65 and p50) found in A-375 after TRAIL treatment (100 ng/ml), whereas there was no blocking effect of DR5 antibodies (Figure 2 ).
No changes in the levels of antiapoptotic proteins after TRAIL treatment but decrease of DR4 in SK-Mel-13 We further investigated whether activation of NF-kB via DR4 may trigger expression of antiapoptotic proteins. DR4-positive (A-375, SK-Mel-13) and DR4-negative cells (Mel-HO) were treated for 24 h with TRAIL and TNF-a, respectively. Western blot analyses for antiapoptotic proteins (Survivin, Bcl-x L , XIAP, Livin, Bcl-2 and c-FLIP) did not reveal significant changes after treatment despite some tendency for increased Survivin in A-375 and Mel-HO (Figure 3a) .
To rule out that a wrong time point after TRAIL treatment was used for identifying upregulation of antiapoptotic factors, the levels of XIAP, c-FLIP and Survivin were also investigated at earlier times after TRAIL treatment (6 and 12 h for SK-Mel-13 and A-375) as well as to a later time point (48 h, for SK-Mel-13). Investigation of 48 h was not possible for A-375 due to massive apoptosis in these cells. As for 24 h, no significant change of these factors was seen throughout the time kinetics applied (Figure 3b) .
Besides possible antiapoptotic functions, NF-kB has been reported to induce the expression of several cytokines, in particular interleukin (IL)-8, which is then secreted (Karin and Greten, 2005) . To check whether high NF-kB activation induced by TRAIL in melanoma cells may trigger the expression of other proteins than antiapoptotic proteins, the secretion of IL-8 by melanoma cells was monitored in supernatant culture medium 12 h after treatment with TRAIL (100 ng/ml). These experiments showed that secretion of IL-8 protein was significantly increased by TRAIL only in the two DR4-positive, NF-kB-responsive melanoma cell lines A-375 and SK-Mel-13, thus indicating that TRAILinduced NF-kB was also active in these cells (Figure 3c) .
In contrast to unchanged expression of antiapoptotic proteins, a significant downregulation of DR4 protein was found in SK-Mel-13 cells after TRAIL treatment. Downregulation of DR4 also occurred in some A-375 cultures but was not always reproducible. No changes, however, were seen for DR5 in the cell lines investigated (Figure 3d) . Interestingly, this effect of TRAIL was completely reverted by pretreatment for 2 h with the proteasome inhibitor LLnL as shown in a kinetic study (Figure 3e ). In separate experiments, LLnL has been shown to prevent TRAIL-induced NF-kB activation in SK-Mel-13 cells (data not shown).
With respect to cell survival, LLnL pretreatment significantly increased the killing effect of TRAIL in all investigated melanoma cell lines, including Mel-HO and SK-Mel-23, in which TRAIL did not induce NF-kB activity (Figure 3f ). The synergism found for the combined treatment of TRAIL and LLnL seems, therefore, not related to a blocking of TRAIL-induced NF-kB activation by LLnL. For SK-Mel-13, DR4 downregulation may contribute to its enhanced sensitivity.
Transient resistance of DR4-positive melanoma cells selected with TRAIL TRAIL-resistant cell populations were selected from the three TRAIL-sensitive cell lines A-375, SK-Mel-13 and Mel-HO by continuous culturing in the presence of TRAIL for 8-10 weeks. Selected cell populations could be cultured at TRAIL concentrations of up to 100 ng/ ml. Starting from these resistant populations, recovery of sensitivity was monitored 1 and 3 months after TRAIL withdrawal from culture medium. Whereas selected cell populations were largely resistant to TRAIL-induced apoptosis, DR4-positive cell lines recovered sensitivity after 1 month (A-375) or after 3 months (SK-Mel-13). In contrast, the DR4-negative, TRAIL-selected Mel-HO maintained resistance even 3 months after TRAIL withdrawal (Figure 4a) .
Selected, TRAIL-resistant melanoma cells also revealed cross-resistance to the agonistic CD95 antibody CH-11 as well as to TNF-a, and sensitivity to these agonists was also partly recovered after TRAIL withdrawal (data not shown), indicating that resistance Figure 2 High NF-kB-binding activity upon TRAIL treatment is mediated by DR4. A-375 melanoma cells were pre-incubated for 1 h with blocking antibodies specific for DR4 and for DR5, respectively, before cells were further treated with TRAIL (100 ng/ ml, for another 1 h). Relative values of NF-kB nuclear binding activities were calculated with respect to untreated controls, which were set to 1. Mean values and s.d. of three independent experiments are shown. ) and normal human melanocytes (NHM) were treated with 100 ng/ml TRAIL (gray) and were compared with controls (white). Nuclear extracts were prepared 1 h after treatment, and equal amounts of nuclear proteins (7 mg) were analysed by ELISA analysis for the binding activities of the five NF-kB subunits (p65, p50, c-Rel, p52, Rel-B). Data reflect mean values and s.d. of three independent experiments (OD). Significant increases are indicated by asterisks. (b) Nuclear extracts were further submitted to EMSA analysis. Equal amounts of nuclear proteins (7 mg) were used. Cultures treated with TRAIL ( þ ) were compared to untreated cells (À). The shifted bands, which characterize NF-kB-binding activity, are indicated (NF-kB). Supershift complexes are shown on the left for TRAIL-treated A-375 melanoma cells after incubation with specific p65 and p50 antibodies. Two independent experiments revealed highly comparable results. (c) Melanoma cell lines A-375 and Mel-HO were treated with 10 ng/ml TNF-a (gray) and were compared with controls (white). After 1 h, nuclear binding activities of p65 and p50 NF-kB subunits were determined by ELISA. Equal amounts of nuclear proteins (7 mg) were used. Data reflect mean values of the binding activities (OD; three independent cultures of each cell line). Significant increases are indicated by asterisks. (d) Dose dependency. A-375 cells were treated with different concentrations of TRAIL as indicated, and nuclear extracts were prepared after 1 h. Equal amounts of nuclear proteins were analysed for binding activities of NF-kB subunits (p65 and p50) by ELISA. DNA fragmentation rates (below) were determined in parallel cultures treated for 6 h with TRAIL. Mean values and s.d. of two independent experiments are shown. Time dependency. A-375 and Mel-HO were stimulated with TRAIL (100 ng/ml) for the times as indicated. NF-kB-binding activities (p65, p50) and DNA fragmentation were determined from parallel cultures. Mean values and s.d. of three independent experiments are shown. mechanisms also affected general pathways common to all death receptors.
TRAIL resistant melanoma cells show reduced activation of NF-kB Nuclear binding activities of p65 and p50 were determined after TRAIL and after TNF-a treatment in A-375, SK-Mel-13 and Mel-HO parent and selected cell cultures. TRAIL-induced NF-kB activation was almost completely blocked in selected SK-Mel-13 cells, and it was reduced in A-375 selected cells. There was no appearance of TRAIL-induced NF-kB activation in selected Mel-HO cells. In contrast, NF-kB activation by TNF-a was not diminished in selected cells (Figure 4b ). Thus, these findings indicate that acquired TRAIL resistance in melanoma cells does not result from NF-kB activation.
TRAIL resistance of melanoma cells is related to downregulation of initiator caspases and DR4
For understanding the nature of TRAIL resistance and recovery of sensitivity in melanoma cells, we investigated the expression of a panel of anti-and proapoptotic factors by Western blot analysis in parent cells, selected cells and cells collected 1 month after TRAIL withdrawal. No change of expression was seen for the antiapoptotic proteins Survivin, XIAP, Livin, Bcl-2, c-FLIP and Bcl-x L as well as for the proapoptotic factors DR5, caspase-3, caspase-7, Bax and Bak. However, downregulation of both initiator caspases of the extrinsic pathway (8 and 10) was found in all three selected, TRAIL-resistant cultures. Their expression seemed to be recovered 1 month after TRAIL withdrawal completely for A-375, but only partly for SK-Mel-13 and Mel-HO. In addition, there was a strong decrease of DR4 in SK-Mel-13 and of Bid in Mel-HO selected cells, which appeared also partly recovered after 1 month (Figure 5a  and b) .
To investigate the causes of long-term resistance of selected Mel-HO cells, the expression of initiator Figure 4 Reduced activation of NF-kB in TRAIL-resistant melanoma cells. Three parent melanoma cell lines (Par) were investigated: A-375, SK-Mel-13 and Mel-HO. TRAIL-resistant subcultures (Sel) were selected by continuous cultivation for 8-10 weeks in presence of TRAIL. Recovery of TRAIL sensitivity was monitored 1 month (W1) and 3 months after withdrawal of TRAIL (W3). (a) DNA fragmentation rates were determined 6 h after starting treatment with TRAIL (20 and 100 ng/ml) and were compared to untreated controls. The controls of the parent cells were set to 1 for each cell line. Mean values and s.d. of three independent experiments each performed in duplicates are shown. (b) Parent and selected melanoma cell lines (A-375, SK-Mel-13, Mel-HO) were treated with TRAIL (100 ng/ml) or with TNF-a (10 ng/ml) as indicated below. Nuclear extracts were prepared 1 h after starting treatment. Equal amounts of nuclear proteins (7 mg) were analysed for binding activities of NF-kB subunits p65 and p50 by ELISA. Data reflect relative values of the binding activities as compared to untreated controls (means and s.d. of three independent cultures for each cell line). Proteins were extracted 24 h after treatment with TRAIL (100 ng/ml) and TNF-a (10 ng/ml), respectively. They were compared to untreated controls. Equal protein amounts (40 mg/lane) were loaded, and consistent blotting was proven by ponceau staining and by evaluation of b-actin expression shown below. Molecular weights are indicated on the left. Two experiments for each cell line starting from independent cultures revealed highly similar results. (b) A kinetics for expression of XIAP, c-FLIP and Survivin in A-375 and SK-Mel-13 melanoma cells was determined by Western blot analysis of proteins extracted at 0, 6, 12, 24 and 48 h after TRAIL treatment (100 ng/ml). (c) Secretion of IL-8 was analysed by ELISA of culture supernatants. Melanoma cell lines were treated with 100 ng/ml TRAIL for 12 h (gray) and were compared with controls (white). Mean values and s.d. of IL-8 protein amounts (ng/ml culture medium) were calculated according to a standard curve from five individual values of two independent experiments. Asterisks indicate significant increases (Po0.005). (d) Four melanoma cell lines were treated with 100 ng/ml TRAIL ( þ ) and were compared to untreated control (À). Protein extracts were prepared after 24 h, and equal protein amounts (40 mg per lane) were loaded for determination of DR4 and DR5 expression by Western blot analysis. Three experiments for each cell line starting from independent cultures revealed highly similar results, namely downregulation of DR4 by TRAIL in SK-Mel-13. (e) SK-Mel-13 cells were pretreated with the proteasome inhibitor LLnL (5 mM), 2 h before starting TRAIL treatment (100 ng/ml). The time dependency of DR4 and DR5 levels was determined by Western blots analysis 0, 6, 12 and 24 h after starting TRAIL treatment in LLnL-pretreated cells ( þ ) and cells that did not received LLnL (À). The proteasome inhibitor was present throughout the experiment. Two experiments starting from independent cultures revealed highly similar results. (f) Four melanoma cell lines were pretreated with the proteasome inhibitor LLnL (5 mM), 2 h before starting TRAIL treatment (100 ng/ml, for 24 h). Survived cells were subjected to a crystal violet viability assay. Relative cell numbers were normalized to untreated controls, which were set to 100% for each cell line. Means and s.d. of two independent experiments performed in triplicate are presented.
TRAIL resistance of melanoma BM Kurbanov et al caspases and of Bid was also monitored in cultures that were grown for 3 months after TRAIL withdrawal (W3). After 3 months, expression of these proteins was found fully restored indicating that additional factors may be responsible for the long-term TRAIL resistance in selected Mel-HO (Figure 5c ).
TRAIL sensitivity can be restored by overexpression of initiator caspases and DR4 and is decreased by siRNA For proving the significance of downregulated initiator caspases and DR4, selected A-375 and SK-Mel-13 cells were transiently transfected with expression plasmids encoding caspase-8, caspase-10, DR4 or DR5. Owing to insufficient transfection efficiency, Mel-HO was not included in these experiments. Instead, we employed the parent melanoma cell line MeWo, which we had previously characterized as TRAIL resistant, DR4 negative, DR5 positive and with weak expression of initiator caspases (Kurbanov et al., 2005) .
Overexpression of caspase-8 as well as of caspase-10 after transient transfection was able largely to restore TRAIL sensitivity in A-375 and in SK-Mel-13 selected cells as well as in resistant MeWo cells (Figure 6a ). Some increase of basic apoptosis found after caspase-8 transfection might be the result of its spontaneous cleavage seen as 41 and 43 kDa cleavage products (Figure 6b) . Similarly, overexpression of DR4 significantly increased TRAIL sensitivity in these cells. In clear contrast, massive overexpression of DR5 remained without effect on TRAIL sensitivity (Figure 6c ). Overexpression was confirmed by Western blot analysis (Figure 6b and d) .
As an additional proof for the significant role of initiator caspases in TRAIL resistance of DR4-positive melanoma cells, siRNA against caspase-8 was applied in A-375 and SK-Mel-13. Downregulation of caspase-8 in these cells by siRNA was accompanied by significant reduction of their TRAIL sensitivity (Figure 7a ). The downregulation of caspase-8 as compared to mock-transfected cells was demonstrated by Western blot analysis (Figure 7b) .
As a parallel approach, selective inhibitors for caspase-8 and for caspase-10 as well as the pan-caspase inhibitor z-VAD were used for treatment of A-375 and SK-Mel-13. As in the siRNA experiments, selective inhibition of initiator caspases reduced the TRAIL sensitivity of these cells (Figure 7a ). Thus, downregulation of both initiator caspases and of DR4 appeared as critical factors leading to TRAIL resistance in melanoma cells.
Discussion
Unlike other death ligands, TRAIL bears the potential for targeting cancer cells in a selective way. Clinical trials with TRAIL or agonistic monoclonal antibodies for its receptors have been initiated for some solid tumors, however, so far excluding melanoma (Fischer and Schulze-Osthoff, 2005) . In a previous study, we have shown that melanoma cells subdivide into two groups dependent on their DR4 expression: DR4-positive cells were highly responsive to TRAILinduced apoptosis, whereas most DR4-negative (DR5-positive) cells were resistant. Furthermore, DR4 was expressed in the majority of primary melanomas in vivo, thus suggesting TRAIL-or DR4-based strategies for therapeutic approaches also in melanoma (Kurbanov et al., 2005) .
Apoptosis resistance, however, is a major problem of almost any cancer therapy. Also in the present paper, we found TRAIL resistance occurring in melanoma cells upon continuous culturing in the presence of TRAIL. Resistance to TRAIL-induced apoptosis has been discussed to correlate with the expression of antiapoptotic proteins such as c-FLIP, Bcl-x L, Bcl-2 and IAP family members (Zhang and Fang, 2005) , whereas in melanoma, the cause of TRAIL resistance was less clear as no correlation was seen to above-listed proteins (Chawla-Sarkar et al., 2002; Zhang et al., 2003) .
Antiapoptotic programs may be driven by the transcription factor NF-kB, which can upregulate antiapoptotic proteins of the Bcl-2 and IAP families (Karin and Lin, 2002) . It may further initiate downregulation of death receptors including the receptors for TRAIL . Further linking the death ligand and NF-kB pathways, it has been shown that death ligands can also trigger NF-kB activation (Ivanov et al., 2003) . A TRAIL-mediated NF-kB activation has been discussed as the cause of TRAIL resistance in Jurkat and cholangiocarcinoma cells (Ehrhardt et al., 2003; Ishimura et al., 2006) . A similar relation has been suggested for melanoma, however, also TRAIL-sensitive cell lines with high basic NF-kB activity have been described (Franco et al., 2001) , and they were also seen in the present paper (Mel-HO).
TRAIL-induced NF-kB activation may be trigged by both agonistic TRAIL receptors, as has been shown for HeLa cells (Harper et al., 2001) . In myeloid leukemia cells and in normal keratinocytes, only DR4 contributed to NF-kB activation (Leverkus et al., 2003a; Secchiero et al., 2003) , whereas in Jurkat cells NF-kB is activated by DR5 (Zauli et al., 2005) . For melanoma cells, we found here TRAIL-induced activation of NF-kB exclusively by DR4 (2/2 cell lines), which was unequivocally proven by selective blocking of one or the other receptor. On the other hand, in two melanoma cell lines and normal melanocyte cultures, which expressed DR5 but lacked DR4, NF-kB activation by TRAIL was insignificant irrespectively of their apoptosis sensitivity. Thus in melanoma cells, DR4 triggers not only high apoptosis but also NF-kB activation, and both responses seem to be linked with each other in these cells.
It is generally accepted for TNF-a that its proapoptotic activity is modulated by simultaneous activation of NF-kB resulting in an upregulation of antiapoptotic factors (Karin and Lin, 2002) . In leukaemia cells, induction of Bcl-x L by TRAIL, via NF-kB, has been correlated with TRAIL resistance (Ravi et al., 2001) . Similarly, antiapoptotic effects of TRAIL-induced NF-kB activation have been proposed also for melanoma; however, the mechanisms remained elusive (Franco et al., 2001) . In the present study, we could not find significant changes in the expression levels of antiapoptotic proteins in melanoma cells upon treatment with TRAIL, thus no indication for an antiapoptotic contribution of TRAIL-activated NF-kB.
Proteosomes contribute to cellular homeostasis by direct or indirect regulation of intracellular protein levels, including those regulating apoptosis (Voorhees et al., 2003) . Thus, proteasome inhibition may also increase the efficacy of TRAIL-based regimens in cancer. As one of their main effects, proteasome inhibitors prevent degradation of inhibitors of kappa B (IkBs) and in turn lead to inhibition of NF-kB. Proteasome inhibitors have been shown to enhance TRAIL-induced apoptosis and this effect has been attributed to decreased NF-kB activities in myeloma, pancreatic cancer and lymphoma cells (Mitsiades et al., 2001; Ehrhardt et al., 2003; Bai et al., 2005) .
However, the selective suppression of NF-kB by a mutated I-kB failed to increase TRAIL sensitivity in other cell systems (Ganten et al., 2005) , what may be seen as an indication for other proteins in TRAIL pathways modulated after proteasome inhibition (Leverkus et al., 2003b) . In this regard, proteasome inhibitors were shown to exert their proapoptotic effects by stabilizing death receptors as reported for prostate carcinoma cells, or Nbk/Bik as reported for colon cancer cells (Johnson et al., 2003; Zhu et al., 2005) .
In our study, a significant increase of TRAIL sensitivity was observed in melanoma cells after proteasome inhibition, however, a similar response was also seen in cells, which did not even activate NF-kB upon TRAIL treatment. As a clear indication for supplementary effects, we found that proteasome inhibition prevented the TRAIL-induced downregulation of DR4.
Further understanding of TRAIL resistance may be provided by the selection of resistant cells (Ehrhardt et al., 2003; Jin et al., 2004) . After establishing this model for DR4-positive melanoma cells, we looked for changes in TRAIL-induced NF-kB activity. However, no increase was found in selected, TRAIL-resistant cells, and again, there were no changes in the expression levels of antiapoptotic proteins as compared to the parent cells.
Thus, (i) TRAIL-induced NF-kB activity was found in highly apoptosis-sensitive melanoma cells, (ii) activated NF-kB did not trigger the expression of antiapoptotic proteins, (iii) enhancement of TRAIL-induced apoptosis by proteasome inhibition was independent of NF-kB and (iv) selected, TRAIL-resistant melanoma cells did not reveal enhanced NF-kB activity. According to these four lines of evidence, we may suggest that TRAIL-induced NF-kB activity does not contribute, in a critical way, to TRAIL resistance in melanoma cells.
So what then caused TRAIL resistance in melanoma cells? This question was addressed with our TRAILresistance cell culture model. The initiator caspase-8 is well known as a key mediator for death ligand-induced apoptosis, and its deficiency has been reported to correlate with TRAIL resistance in other tumor models (Eggert et al., 2001; Fulda et al., 2001) . The role of the initiator caspase-10 in TRAIL-induced apoptosis is, however, less well understood. In lung and breast cancer cells, TRAIL-induced apoptosis is mediated by caspase-10 (Kischkel et al., 2001 ), but it could not substitute for caspase-8 in Jurkat cells (Sprick et al., 2002) . In the present study, we found strong downregulation of both initiator caspases in DR4-positive melanoma cells selected for TRAIL resistance, and their expression had come back in cells with recovered TRAIL sensitivity. As a proof of principle, transient transfection and overexpression of one of these caspases could largely restore apoptosis sensitivity in resistant cells. In complementary experiments, siRNA or selective peptide inhibitors against initiator caspases significantly reduced TRAIL-induced apoptosis, thus strongly supporting their significant role for TRAIL sensitivity.
Melanoma cell lines, seem to reveal different types of TRAIL resistance. Whereas in A-375 a quick recovery of initiator caspases coincided with recovered TRAIL sensitivity, in SK-Mel-13 partial recovery of initiator caspases and DR4 after 1 month was not sufficient for restoring TRAIL sensitivity. Sensitivity was, however, recovered in these cells after 3 months. In contrast, selected DR4-negative Mel-HO cells revealed long-term TRAIL resistance despite of a recovery of initiator caspases and Bid after 3 months. These different characters may also correspond to different types of TRAIL resistance in melanoma in the clinic. The findings on DR4-negative cells were supported recently by another set of DR4-negative (DR5-positive) melanoma cell lines, which also showed downregulation of caspase-8 but not of caspase-10 and in addition downregulation of proapoptotic Bcl-2 proteins such as Bim, PUMA, Noxa, Bad in selected, TRAIL-resistant cells (Zhang et al., 2006) . Thus, different apoptosis regulators may contribute to TRAIL-resistance of DR4-negative melanoma cells.
Particular roles of Bax and Bak have been discussed for TRAIL sensitivity in thyroid, prostate and colon tumor cells when combined with chemo-or radiotherapy (von Haefen et al., 2004; Wang et al., 2004; Wendt et al., 2005) . For melanomas, the expression of Bax and Bak has been regarded as independent prognostic markers for predicting melanoma progression (Fecker et al., 2006) . However, no change of Bax or Bak was seen here in selected, TRAIL-resistant melanoma cells. Also in other cell systems, Bcl-2 proteins seemed less decisive for TRAIL resistance, as neither Bcl-2 overexpression in Jurkat cells nor Bax deficiency in colon carcinoma cells were able to completely abolish TRAIL sensitivity (Johnson et al., 2003; He et al., 2004; Rudner et al., 2005) . Downregulation of death receptors represents a general way for acquiring apoptosis resistance to extrinsic signals, as found for CD95 in lymphoma cells (Li-Weber and Krammer, 2003) . In carcinoma cells from lung, colon and breast, resistance to TRAIL-induced apoptosis was associated with low surface expression of DR4 (Kim et al., 2000; Jin et al., 2004) . For melanoma, downregulation of DR5 has so far been regarded as a contributing issue in TRAIL resistance (Nguyen et al., 2001) . In contrast, in the DR4-positive melanoma cells investigated here, downregulation of DR4 turned out as a critical event for TRAIL resistance, indicated by loss of DR4 in resistant cells and its re-expression in cells that had recovered sensitivity. Also, exogenous expression of DR4 in resistant cells could largely restore TRAIL sensitivity, whereas even massive overexpression of DR5 remained without any effect on sensitivity.
These data again proved the dominant role of DR4 over DR5 for TRAIL-induced apoptosis in melanoma cells. Even further supporting these findings, TRAIL sensitivity could also be restored by exogenous expression of initiator caspases or DR4 in originally TRAILresistant melanoma cells, which were not in vitro selected, indicating that loss of these factors may be a more common mechanism in melanoma cells critical for TRAIL resistance.
In conclusion, resistance to TRAIL-induced apoptosis in melanoma cells seemed to be based on downregulation of initiator caspases and of DR4 but unrelated to NF-kB-driven upregulation of antiapoptotic factors. Resistance of DR4-positive cells was only transient, in contrast to DR4-negative cells, where it was not reversible. These findings may also be of some significance for clinical trials to be initiated in melanoma. Expression of DR4 and caspases seems to be clearly supportive for sensitivity. Levels of these factors may be increased by proteasome inhibition, which prevented TRAIL-induced downregulation of DR4 (shown here), by chemotherapeutics, which may upregulate TRAIL death receptors (Singh et al., 2003) or by interferon-g, which was shown to upregulate initiator caspase-8 (Fulda and Debatin, 2006) . Transient resistance of melanoma cells may also be circumvented by temporary interrupted administrations.
Finally, melanoma cells subdivide into two classes with respect to DR4 expression. For DR4-positive cells, high apoptosis sensitivity as well as NF-kB activation and development of only transient resistance became evident, thus possibly characterizing patients, which may benefit from TRAIL-based therapies. Routine investigations of the status of death receptors and initiator caspases may thus be helpful for appropriate stratification of melanoma patients.
Materials and methods
Cell culture
The human melanoma cell lines A-375, Mel-HO, SK-Mel-13, SK-Mel-23 and MeWo were used in the present study. They were maintained in Dulbecco's modified Eagle's medium (DMEM) (4.5 g/l glucose; Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum and antibiotics (Biochrom, Berlin, Germany). Cultures of normal human melanocytes (NHM) were established from different foreskins by trypsin digestion and were cultivated as described previously in serum-free melanocyte growth medium (Eberle et al., 1999) . Cells were grown at 371C and 5% CO 2 .
For induction of apoptosis, soluble human killerTRAIL, (Alexis, Gruenberg, Germany ALX-201-073-C020) was applied in concentrations of 20 and 100 ng/ml. Cells were seeded in six-well plates (2 Â 10 5 cells/well), and after 24 h the supernatant was replaced by TRAIL-containing growth medium. If not stated differently, incubation with TRAIL was carried out for 6 h (apoptosis) and for 1 h (NF-kB activation), respectively. For experiments applying DR4 and DR5 blocking antibodies, 1 Â 10 6 cells were incubated for 24 h in culture flasks before addition of new growth medium containing 10 mg/ml of the respective blocking antibody: mouse monoclonal TRAIL-R1/DR4 (Alexis, clone HS101, ALX-804-297-C100) or mouse monoclonal TRAIL-R2/DR5 (Alexis, clone HS 201, ALX-804-298-100). After 1 h, 100 ng/ml TRAIL was added, and incubation was continued for another 1 h, before analysis of NF-kB.
For experiments with selective caspase inhibitors, cells were seeded in 24-well plates (5 Â 10 4 cells/well). After 24 h, growth medium was replaced by 1 ml medium containing 20 mM of caspase-8 (z-IETD-FMK), caspase-10 (z-AEVD-FMK) or a pan-caspase inhibitor (z-VAD-FML) (R&D Biosystems, Minneapolis, MN, USA; FMKSP01). After another 1 h, cells were treated with TRAIL (20 ng/ml) for additional 6 h.
Selection of TRAIL-resistant melanoma cells
A-375, SK-Mel-13 and Mel-HO (parent) melanoma cell lines were seeded in culture flasks (1 Â 10 6 cells/flask) and were continuously treated for 8-10 weeks with 100 ng/ml TRAIL. Growth medium with new TRAIL was changed two times a week. When selected cells had reached confluence, they were passaged and were continuously kept in growth medium with 5 ng/ml TRAIL (selected cells). For recovering TRAIL sensitivity, selected cultures were subjected to TRAIL withdrawal for 1 month (W1) and for 3 months (W3), respectively.
Quantification of apoptosis
Apoptosis was quantified with a cell death detection ELISA (Roche Diagnostics, Mannheim, Germany), which detects mono-and oligonucleosomes formed in apoptotic cells. Protocols for the assay were described elsewhere (Eberle et al., 2003) . Relative apoptosis values were calculated with respect to untreated control cells.
Determination of IL-8 secretion
Secretion of IL-8 by melanoma cells into supernatant culture medium was analysed by ELISA (Human CXCL8/IL-8 DuoSet, DY208; R&D Biosystems). Cells were seeded in sixwell plates with 2 Â 10 5 cells/well. After 24 h, growth medium was replaced by 1 ml medium containing 100 ng/ml TRAIL. After another 12 h, the supernatant was removed and subjected to ELISA assay. The optical density of triplicate samples was determined at 450 nm in an ELISA reader. A background correction was carried out by subtracting the values at 540 nm. IL-8 protein amounts (ng/ml culture medium) were calculated according to a standard curve determined in parallel.
Proteasome inhibition and in vitro viability assay Cells were seeded in 24-well plates with 5 Â 10 4 cells/well. After 24 h, growth medium was replaced by 0.25 ml medium containing the proteosome inhibitor N-Acetyl-Leu-Leu-Nle-CHO (LLnL, 5 mM; Calbiochem, San Diego, CA, USA). After another 2 h, cells were treated with TRAIL (100 ng/ml) for additional 24 h. Cells were then fixed with 1% glutaraldehyde in PBS for 1 h and were stained with 0.01% crystal violet in PBS for 1 h. Attached cells were washed with deionized water, and were dried. Crystal violet absorbed by cell nuclei was solubilized in phosphate-buffered saline (PBS)/0.2% Triton X-100. The optimal density was determined at 550 nm by ELISA.
NF-kB activity by ELISA NF-kB nuclear-binding activity was determined by using the TransAM NF-kB family ELISA kit (Active Motif, Rixensart, Belgium). This ELISA detects the NF-kB subunits p65, p50, c-Rel, Rel-B and p52 (Secchiero et al., 2003) . Melanoma cells (2 Â 10 6 ) were seeded in culture plates (50 cm 2 ) and were treated with TRAIL (varying times and concentrations). For blocking experiments, cells were pretreated with blocking antibodies as described above. Nuclear extracts were prepared by a nuclear extraction kit (Active Motif). The protein content in nuclear extracts was quantified by the BCA protein assay (Pierce, Bonn, Germany). Equal amounts (7 mg) of nuclear proteins were placed into a 96-well plate coated with oligonucleotides that cover the NF-kB consensus sequence. Binding of the different NF-kB subunits to the immobilized oligonucleotides was detected by using subunit-specific antibodies followed by immunostaining with horseradish peroxidase-labelled secondary antibodies. The chromogenic reaction was measured at 450 nm in an ELISA reader.
Electromobility shift assays
Nuclear extracts prepared by the nuclear extraction kit (Active Motif) were further used for EMSA. Two complementary oligonucleotides covering the NF-kB consensus sequence were used: 5 0 -AGCTTCAGAGGGGACTTTCCGAGAGG -3 0 (sense) and 3 0 -AGTCTCCCCTGAAAGGCTCTCCAGCT -5 0 (antisense). The annealed oligonucleotides were radiolabeled by filling up the overhanging ends with 32 P-dCTP (PerkinElmer, Rodgau, Germany) and Klenow polymerase (Invitrogen, Karlsruhe, Germany). Binding reactions were carried out at room temperature for 30 min. For one reaction, 7 mg of nuclear extract and 10 5 c.p.m. of 32 P-labeled, double-stranded oligonucleotide were applied in 20 ml binding buffer (20 mM Hepes, 60 mM KCl, 4% Ficoll, pH 7.9, 2 mM dithiotheritol (DTT), 100 mg/ml bovine serum albumin (BSA) and 100 mg/ml poly d(I-C)). Samples were analysed by electrophoresis on 5% nondenaturing polyacrylamide gels using 0.5 Â Tris-Borate-EDTA (TBE) buffer, pH 8.0. Dried gels were exposed to an imaging plate for quantification of radioactivity by a BAS-1500 Phosphoimager (Fuji Photo, Nakanuma, Japan). Supershift controls were performed by using antibodies specific for NF-kB subunits p50 and p65 (sc-1191; sc-109; Santa Cruz Biotechnology, Heidelberg, Germany).
Transient transfection and application of small interfering RNA (siRNA) For overexpression of caspases and death receptors, melanoma cell lines were transiently transfected with expression plasmids, as described previously (Eberle et al., 2003) . An expression plasmid containing the full-length cDNA of caspase-8 under control of a HTLV promoter (ORF9-hCASP8b; Cayla-InvivoGen, Toulouse, France) was used as well as three plasmids containing full-length cDNA under control of a CMV promoter: caspase-10 (pCMV-SPORT6-caspase-10; RZPD, Berlin, Germany), DR4 (pCMV-SPORT6-DR4; RZPD) and DR5 (pCMV-SPORT6-DR5; RZPD). Transfection solutions consisted of 1 ml/well (six-well plate) of Opti-MEM supplemented with 1 ml of DMRIE-C (Invitrogen) and 0.8 mg plasmid DNA (for caspase-8 and caspase-10) or 0.2 mg plasmid DNA (for DR4 and DR5). After transfection, cells were incubated for 48 h in normal growth medium, for recovery, before they were treated with TRAIL (20 ng/ml, 6 h).
For siRNA experiments, transfection solutions consisted of 1 ml Opti-MEM medium (per well of a six-well plate) supplemented with 1.4 ml DMRIE-C (Invitrogen) and 80 pmols caspase-8 siRNA or control siRNA (Santa Cruz Biotechnology; sc-29930; sc-37007). After transfection, cells were incubated for 48 h in normal growth medium, for recovery, before they were treated with TRAIL (20 ng/ml, 6 h). Parallel cultures were subjected to caspase-8 protein expression analysis by Western blotting.
Western blot analyses
Protein extraction, protein quantification and Western blot analyses have been described previously (Kurbanov et al., 2005) . The following antibodies were used here for Western blot analysis: TRAIL-R1/DR4 (Acris Antibodies, Hiddenhausen, Germany; ab8414, 1:1000); TRAIL-R2/DR5 (Acris Antibodies; ab8416, 1:1000); caspase-8 (New England Biolabs, 
Statistical analyses
Assays consisted of duplicate or triplicate values, and two or three independent experiments were performed. Mean values and s.d. were calculated from the individual values of all independent experiments. Statistical significance was determined by Student's t-test.
Abbreviations
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL-R1/DR4, TRAIL receptor 1/death receptor 4; TRAIL-R2/DR5, TRAIL receptor 2/death receptor 5; NF-kB, nuclear factor kappa B.
